TAI Diagnostics Overview
Latest Deal Type
Series A
Latest Deal Amount
$12.8M
TAI Diagnostics General Information
Description
Developer of a diagnostic test designed to monitor the health of transplanted organs. The company's test which utilizes cf-dna technology as a direct measurement of organ injury through quantitation of donor-specific cf-dna released into the bloodstream from injured cells of a transplanted organ, enabling physicians to detect rejection early and perform surveillance biopsies at regular intervals caused by a deletion from chromosome 22 at the q11 location.
Want to dig into this profile?
We’ll help you find what you need
Learn more
TAI Diagnostics Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 2. Early Stage VC (Series A) |
30-May-2018 |
$12.8M |
000.00 |
000.00 |
Completed |
Generating Revenue |
| 1. Early Stage VC (Series A) |
23-Oct-2015 |
00.00 |
00.00 |
0000 |
Completed |
Startup |
TAI Diagnostics Executive Team (3)
| Name |
Title |
Board Seat |
Contact Info |
| Frank Langley |
Chief Executive Officer & Board Member |
|
|
| Aoy Tomita-Mitchel Ph.D |
Co-Founder, Chief Scientific Officer & Board Member |
|
|
| Paula North Ph.D |
Chief Laboratory Officer & Medical Director |
|
|